Sledge GW, Toi M, Neven P, et al. MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy. J Clin Oncol. 2017;35 (suppl; abstr 1000).
Ceritinib versus chemotherapie bij gevorderd ALK-positief NSCLC: ASCEND-4
mrt 2017 | Longoncologie